Page 2 - Sabcs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sabcs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sabcs Today - Breaking & Trending Today

HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer. ....

San Antonio , United States , Saraa Hurvitz , Trastuzumab Emtansine , Primary Analysis , Double Blind Phase , Previously Treated , Metastatic Breast , Partnership With , Antonio Breast Cancer Symposium , Breast Cancer , Her2 Metastatic Breast Cancer , Her2 Positive Metastatic Breast Cancer , Her2 Breast Cancer , Her2 Positive Breast Cancer , Her2climb 02 , Clinical Implications ,

ICYMI: Highlights From SABCS 2023

This year’s top content from the annual San Antonino Breast Cancer Symposium (SABCS) is concentrated in 3 areas: health equity, benign breast disease, and fertility preservation following diagnosis.
....

Memorial Sloan Kettering Cancer Center , Antonino Breast Cancer Symposium , Cancer Care Highlight Multifactorial Equity , Precision Prevention , Benign Breast , Ethnicity May Influence Local Recurrence , Patients With Breast Cancer Attempting , San Antonino Breast Cancer Symposium , Care Equity , Benign Breast Disease ,

Quality of Life, Toxicity Weighed Most by Patients When Choosing Metastatic Breast Cancer Treatment

Quality of life and adverse effects are key components most patients with estrogen receptor–positive, HER2-negative metastatic breast cancer weigh when choosing an anticancer therapy, according to patient-reported results of an ESR1 QUAlity of Life Survey 3 survey. ....

San Antonio , United States , Sarahl Sammons , Dana Farber Cancer Institute , Quality Of Life , Media Group , Life Survey , Antonio Breast Cancer , Metastatic Breast Cancer , Breast Cancer , Adverse Effects , Esr1 Quality Of Life Survery 3 , Equals 3 , San Antonio Breast Cancer Symposium ,

ESR1 Coalteration Treatment Resistance Does Not Impact Lasofoxifene/Abemaciclib Efficacy in ESR1+ Metastatic Breast Cancer

The presence of ESR1 coabnormalities, including TP53 and PIK3CA mutations, and CCND1 and FGFR1 amplification, did not demonstrate a negative impact on the efficacy with lasofoxifene and abemaciclib in patients with estrogen receptor–positive, ESR1-mutant metastatic breast cancer.
....

San Antonio , United States , Dsenthil Damodaran , University Of Texas Md Anderson Cancer Center , Antonio Breast Cancer Symposium , Cancer Center , Metastatic Breast Cancer , Breast Cancer , San Antonio Breast Cancer Symposium , Phase 2 Elaine Study , Esr1 Coalteration , Tp53 And Pik3ca , Estrogen Receptor Positive ,

Higher Survival Rates Found in Male Hispanic, API Patients With Early Breast Cancer

These findings suggest that addressing socioeconomic disparities and inequities that impact access to health care and services may help improve survival outcomes across racial/ethnic groups of male patients with early breast cancer. ....

United States , National Cancer Database , Pacific Islander , San Antonio Breast Cancer Symposium , Cancer Database , Hispanic Black , Hispanic White , Namong Productions , Breast Cancer , Male Patients With Breast Cancer , Black Patients , White Patients , Hispanic Patients , Api Patients , Overall Survival Rate , Mortality Rate ,